top of page

- 0 min read

(BPRW) Vivacelle Bio Announces Early Results of its Phase IIa Clinical Trial of VBI-S for Improving Hypovolemia Due to Sepsis

Recent Posts

Vivacelle Bio Enrolls First Patient in Phase 3 Trial of Hypovolemia Due to Septic Shock for Phospholipid Nanoparticle-Based VBI-S

KANSAS CITY, Mo., Sept. 3, 2024 /PRNewswire/ -- Vivacelle Bio , a late-stage biopharma company developing life-saving treatments for...

Surge in Septic Shock Care: Vivacelle’s Innovative Approach

Vivacelle Bio Initiates Phase 3 Trial for Lead Asset VBI-S to Treat Patients with Hypovolemia Due to Septic Shock

Comments

bottom of page